Efficacy of Olaparib (ola) Plus Abiraterone (abi) Vs Placebo (pbo) Plus Abi in the Non-Brca Mutation (non-Brcam) Subgroup of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcprc) in the Propel Trial
| dc.contributor.author | Mehra, N. | |
| dc.contributor.author | Clarke, N. W. | |
| dc.contributor.author | Armstrong, A. J. | |
| dc.contributor.author | Oya, M. | |
| dc.contributor.author | Shore, N. D. | |
| dc.contributor.author | Procopio, G. | |
| dc.contributor.author | Guedes, J. D. C. | |
| dc.contributor.author | Arslan, Çağatay | |
| dc.date.accessioned | 2023-12-26T07:28:43Z | |
| dc.date.available | 2023-12-26T07:28:43Z | |
| dc.date.issued | 2023 | |
| dc.description | Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Barcelona, SPAIN | en_US |
| dc.description.abstract | [No abstract available] | en_US |
| dc.description.sponsorship | European Soc Med Oncol | en_US |
| dc.description.sponsorship | AstraZeneca; Merck Sharp Dohme LLC | en_US |
| dc.description.sponsorship | AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. | en_US |
| dc.identifier.doi | 10.1016/j.annonc.2023.09.2753 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2023.09.2753 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/5005 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.ispartof | Annals of Oncology | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Efficacy of Olaparib (ola) Plus Abiraterone (abi) Vs Placebo (pbo) Plus Abi in the Non-Brca Mutation (non-Brcam) Subgroup of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcprc) in the Propel Trial | en_US |
| dc.type | Conference Object | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | … | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::conference output | |
| gdc.collaboration.industrial | true | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Mehra, N.] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands; [Clarke, N. W.] Christie & Salford Royal NHS Fdn Trusts, Dept Urol, Manchester, Lancs, England; [Armstrong, A. J.] Duke Univ, Duke Canc Inst, Dept Med, Ctr Prostate & Urol Canc, Durham, NC USA; [Oya, M.] Keio Univ, Dept Urol, Sch Med, Tokyo, Japan; [Shore, N. D.] Carolina Urol Res Ctr, Dept Urooncol, Myrtle Beach, SC USA; [Procopio, G.] Ist Nazl Tumori Milano, Dept Oncol & Haematol, Milan, Italy; [Guedes, J. D. C.] Hosp Base Sao Jose Do Rio Preto, Dept Clin Oncol, Sao Jose Do Rio Preto, Brazil; [Arslan, C.] Izmir Econ Univ, Dept Oncol, Med Pk Hosp, Izmir, Turkiye; [Parnis, F.] Ashford Canc Ctr Res, Dept Oncol, Kurralta Pk, SA, Australia; [Brown, E.] Univ Hosp Southampton, Dept Oncol, Southampton, Hants, England; [Schlurmann, F.] Ctr Hosp Cornouaille, Dept Oncol, Quimper, France; [Joung, J. Y.] Natl Canc Ctr, Dept Urol, Goyang Si, South Korea; [Sugimoto, M.] Kagawa Univ Hosp, Dept Urol, Kagawa, Japan; [Choi, Y. D.] Yonsei Univ, Dept Urol, Coll Med, Seoul, South Korea; [Castellano, D.] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain; [Urun, Y.] Ankara Univ, Dept Med Oncol, Sch Med, Ankara, Turkiye; [Hosius, C.] MSD Sharp & Dohme GmbH, Dept Med Affa | en_US |
| gdc.description.endpage | S976 | en_US |
| gdc.description.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | S975 | en_US |
| gdc.description.volume | 34 | en_US |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W4387810248 | |
| gdc.identifier.wos | WOS:001087480202473 | |
| gdc.index.type | WoS | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 1.0 | |
| gdc.oaire.influence | 2.9045277E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.popularity | 2.9446736E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 0.238 | |
| gdc.openalex.normalizedpercentile | 0.7 | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.crossrefcites | 1 | |
| gdc.plumx.mendeley | 8 | |
| gdc.virtual.author | Arslan, Çağatay | |
| gdc.wos.citedcount | 1 | |
| relation.isAuthorOfPublication | e39c1203-60be-410a-97b3-27cb69d126a9 | |
| relation.isAuthorOfPublication.latestForDiscovery | e39c1203-60be-410a-97b3-27cb69d126a9 | |
| relation.isOrgUnitOfPublication | 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd | |
| relation.isOrgUnitOfPublication | fbc53f3e-d1d3-4168-afd8-e42cd20bddd9 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd |